XON - Intrexon Corporation

NYSE - NYSE Delayed Price. Currency in USD
14.20
+0.46 (+3.35%)
At close: 4:03PM EDT

14.20 0.00 (0.00%)
After hours: 4:35PM EDT

Stock chart is not supported by your current browser
Previous Close13.74
Open13.78
Bid13.38 x 2200
Ask14.89 x 900
Day's Range13.42 - 14.24
52 Week Range10.26 - 20.67
Volume950,597
Avg. Volume1,337,001
Market Cap1.857B
Beta1.59
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire3 days ago

    Research Report Identifies Acushnet, Capitol Federal Financial, Laredo Petroleum, Intrexon, Corning, and Idera Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Acushnet ...

  • ACCESSWIRE7 days ago

    Today's Research Reports on Trending Tickers: Omeros and Intrexon

    NEW YORK, NY / ACCESSWIRE / August 10, 2018 / U.S. markets finished mostly lower on Thursday, as broader market was dragged lower by weak performance from the industrial and energy sector matched with ...

  • PR Newswire7 days ago

    Intrexon Business Update and Conference Call

    The Company is not announcing final financial results for the quarter ended June 30, 2018 and is delaying the filing of its quarterly report on Form 10-Q.  The delay in filing the second quarter report is related to the Company's application of certain aspects of ASC 606 in the Company's first quarter Form 10-Q.  The Company will be filing an amended Form 10-Q for the first quarter of 2018.  The Company expects to file the second quarter report and amended first quarter report within the next few days. Intrexon and Epimeron, Inc., a world-class provider of gene discovery and biosynthetic pathway optimization, announced the isolation and recombinant expression of a novel gene from the opium poppy (Papaver somniferum) encoding the enzyme thebaine synthase.

  • ACCESSWIRE7 days ago

    Intrexon Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Intrexon Corporation (NYSE: XON ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 5:30 PM Eastern Time. ...

  • GlobeNewswire10 days ago

    Ziopharm Oncology Announces Changes to its Board of Directors

    Scott Tarriff, a member of the Board since 2015, has been elected to serve as Lead Director, succeeding Sir Murray Brennan, M.D. Both Sir Dr. Brennan and former U.S. Sen. William Wyche Fowler will step down when their terms expire on September 18, 2018, the date of the annual meeting of shareholders. Doug Pagán and Elan Ezickson have been nominated for election to the Board at the Company’s annual meeting of stockholders.

  • GlobeNewswire10 days ago

    AquaBounty Technologies, Inc. Results for the quarter and six months ended June 30, 2018

    MAYNARD, Mass., Aug. 07, 2018-- AquaBounty Technologies, Inc., a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation, ...

  • PR Newswire14 days ago

    Intrexon to Present at the Jefferies 2018 Global Industrials Conference

    GERMANTOWN, Md. , Aug. 3, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today ...

  • PR Newswire15 days ago

    Intrexon to Announce Second Quarter and First Half 2018 Financial Results on August 9th

    GERMANTOWN, Md. , Aug. 2, 2018 /PRNewswire/ --   Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...

  • GlobeNewswire17 days ago

    Ziopharm Oncology to Announce Second Quarter 2018 Financial Results, Host Conference Call Aug. 8

    The webcast will be recorded and available for replay on the Company's website for two weeks. Ziopharm Oncology is a Boston-based biotechnology company focused on the development of next-generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer. In partnership with Precigen Inc., a wholly-owned subsidiary of Intrexon Corporation (XON), Ziopharm is focused on the development of two platform technologies designed to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of multiple cancer types: Controlled IL-12 and Sleeping Beauty for genetically modifying T cells.

  • GlobeNewswire21 days ago

    Ziopharm Oncology Board Responds to Recent Stock Price Decline

    Ziopharm Oncology, Inc. (ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today responded to the recent stock price decline and announced it expects to add new members to the Company’s Board of Directors and expand its management team. “Over the past year, our Controlled IL-12 and Sleeping Beauty cell therapy platform technologies have progressed, providing a strong scientific foundation for the Company.

  • ACCESSWIRElast month

    Free Technical Research on Intrexon and Three More Biotech Equities

    LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on XON sign up now at www.wallstequities.com/registration. On Tuesday, July 10, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Tuesday's trading session in bullish territories.

  • PR Newswire2 months ago

    Intrexon Announces Pricing of Offerings of Convertible Senior Notes and Common Stock

    GERMANTOWN, Md., June 29, 2018 /PRNewswire/ -- Intrexon Corporation (XON) (the "Company") today announced that it has priced its offering of $200.0 million aggregate principal amount of its 3.50% Convertible Senior Notes due 2023 (the "Notes") in an underwritten offering registered with the Securities and Exchange Commission (the "SEC"). The Notes will be senior unsecured obligations of the Company and will bear interest at a rate of 3.50% per year, payable semiannually in arrears on January 1 and July 1 of each year, beginning on January 1, 2019.  The Notes will mature on July 1, 2023, unless earlier repurchased or converted in accordance with their terms.  Prior to April 1, 2023, the Notes will be convertible at the option of the holder only upon the occurrence of certain events and during certain periods.  On or after April 1, 2023, the Notes will be convertible at the option of the holder at any time until the business day immediately preceding the maturity date.

  • GlobeNewswire2 months ago

    Ziopharm Oncology Enrolls First Patient in Phase 1 Trial Evaluating Combination Therapy of Controlled IL-12 and OPDIVO®

    Ziopharm Oncology, Inc. (ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today announced that it has enrolled the first patient in its Phase 1 clinical trial to evaluate Ad-RTS-hIL-12 plus veledimex in combination with OPDIVO® (nivolumab), an immune checkpoint, or PD-1, inhibitor, in adult patients with recurrent glioblastoma (rGBM). “We are excited about the first-ever dosing of this combination and its potential to bring a potent and controlled anti-tumor immune response to glioblastoma,” said Francois Lebel, M.D., Executive Vice President, Research and Development, Chief Medical Officer at Ziopharm. “By controlling interleukin 12, Ad-RTS-hIL-12 plus veledimex already has shown it can recruit killer T cells into the tumor and increase expression of checkpoints in this microenvironment.

  • PR Newswire2 months ago

    Intrexon Announces Proposed Offerings of Convertible Senior Notes and Common Stock

    GERMANTOWN, Md., June 27, 2018 /PRNewswire/ -- Intrexon Corporation (XON) (the "Company") today announced that it intends to offer and sell, subject to market and other conditions, $200.0 million aggregate principal amount of its Convertible Senior Notes due 2023 (the "Notes") in an underwritten offering registered with the Securities and Exchange Commission (the "SEC").  The Company expects to grant the underwriters of the Notes a 30-day option to purchase up to an additional $30.0 million aggregate principal amount of Notes, solely to cover over-allotments, if any. The Notes will be senior unsecured obligations of the Company, and interest will be payable semi-annually in arrears.  The Notes will be convertible into cash, shares of the Company's common stock ("Common Stock") or a combination thereof, at the Company's election.  The interest rate, conversion rate and other terms of the Notes will be determined upon pricing of the offering of the Notes.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Intrexon

    NEW YORK, NY / ACCESSWIRE / June 20, 2018 / U.S. equities slumped on Tuesday as global trade concerns grew after President Trump threatened to impose an additional $400 billion in tariffs on goods from ...

  • PR Newswire2 months ago

    Oxitec to Apply New Generation of Self-limiting Mosquito Technology to Malaria-spreading Mosquitoes

    Oxitec, Ltd. ("Oxitec"), a wholly owned subsidiary of Intrexon Corporation (XON), today announced it is entering into a cooperative agreement with the Bill & Melinda Gates Foundation ("BMGF") to develop a new strain of Oxitec's self-limiting Friendly™ Mosquitoes to combat a mosquito species that spreads malaria in the Western Hemisphere. The parties will build on Oxitec's successful deployment of Friendly™ Aedes mosquitoes to reduce the vector that spreads dengue, Zika and other diseases and apply the self-limiting and male-selecting technology to anopheline vectors that can spread malaria in endemic regions in the Americas, eastern Africa and South Asia.

  • PR Newswire2 months ago

    Oxitec to Apply New Generation of Self-limiting Mosquito Technology to Malaria-spreading Mosquitoes

    Oxitec, Ltd. ("Oxitec"), a wholly owned subsidiary of Intrexon Corporation (XON) (XON), today announced it is entering into a cooperative agreement with the Bill & Melinda Gates Foundation ("BMGF") to develop a new strain of Oxitec's self-limiting Friendly™ Mosquitoes to combat a mosquito species that spreads malaria in the Western Hemisphere. The parties will build on Oxitec's successful deployment of Friendly™ Aedes mosquitoes to reduce the vector that spreads dengue, Zika and other diseases and apply the self-limiting and male-selecting technology to anopheline vectors that can spread malaria in endemic regions in the Americas, eastern Africa and South Asia.

  • GlobeNewswire2 months ago

    Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy

    Ziopharm, Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (XON) and The University of Texas MD Anderson Cancer Center, the IND sponsor, are seeking to conduct a clinical trial to evaluate CAR+ T cells manufactured with Sleeping Beauty technology as an investigational treatment for patients with relapsed or refractory, CD19+ leukemias and lymphomas. CAR+ T cells very-rapidly manufactured with the Sleeping Beauty platform for this third-generation trial are designed to co-express CD19-specific chimeric antigen receptor, or CAR, membrane-bound interleukin 15 and a safety switch.

  • GlobeNewswire2 months ago

    Ziopharm Oncology Presents Clinical Data Demonstrating Anti-tumor Immune Response of Controlled IL-12 Platform in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting

    -Ad-RTS-hIL-12 plus veledimex recruits T cells into breast and brain cancers- Median overall survival reaches 12.7 months in patients with recurrent glioblastoma in 20 mg veledimex cohort who received ...

  • PR Newswire3 months ago

    Isolation and Recombinant Expression of Key Enzyme for Opioid Production

    Long Postulated Enzyme Thebaine Synthase Potentiates Efficient Biosynthesis of Opioids by Increasing Thebaine Titers 20-fold in Engineered Yeast Strains BUDAPEST, Hungary , May 29, 2018 /PRNewswire/ ...

  • PR Newswire3 months ago

    Oxitec Launches Field Trial in Brazil for Next Generation Addition to Friendly™ Mosquitoes Platform

    Oxitec Ltd, a wholly owned subsidiary of Intrexon Corporation (XON), announced that the newest addition to its Friendly™ Aedes aegypti mosquito line, "OX5034", will initiate open field trials on May 23, 2018. OX5034 is the next generation of Oxitec's non-biting Friendly™ Aedes mosquitoes, designed to reduce populations of the disease-spreading Aedes aegypti mosquito. This first field trial of this second generation Friendly™ Aedes mosquito will take place in Indaiatuba, a municipality in the state of São Paulo and part of the metropolitan region of Campinas, Brazil.

  • PR Newswire3 months ago

    The Cayman Government and Oxitec Launch Innovative Pilot to Suppress Aedes aegypti

    The Cayman Islands' Mosquito Research and Control Unit (MRCU) and Oxitec Ltd. (XON) announced today the launch of a new partnership this year as part of the MRCU's efforts to combat Aedes aegypti mosquitoes in the Cayman Islands. The partnership will focus on implementing a new pilot project that will integrate Oxitec's Friendly™ Aedes aegypti mosquitoes with more traditional methods used in integrated vector management ("IVM") efforts, allowing for the evaluation of a combined approach designed to dramatically suppress this vector of Zika, dengue, yellow fever, and chikungunya.

  • PR Newswire3 months ago

    The Cayman Government and Oxitec Launch Innovative Pilot to Suppress Aedes aegypti

    The Cayman Islands' Mosquito Research and Control Unit (MRCU) and Oxitec Ltd. announced today the launch of a new partnership this year as part of the MRCU's efforts to combat Aedes aegypti mosquitoes in the Cayman Islands. The partnership will focus on implementing a new pilot project that will integrate Oxitec's Friendly™ Aedes aegypti mosquitoes with more traditional methods used in integrated vector management ("IVM") efforts, allowing for the evaluation of a combined approach designed to dramatically suppress this vector of Zika, dengue, yellow fever, and chikungunya.

  • Precigen Announces First Patient Dosed in Phase 1 Clinical Study of INXN-4001
    PR Newswire3 months ago

    Precigen Announces First Patient Dosed in Phase 1 Clinical Study of INXN-4001

    GERMANTOWN, Md., May 21, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced the treatment of the first patient in a Phase 1 first-in-human clinical trial of its investigational therapy, INXN-4001. "This start of dosing is an exciting and important milestone for Precigen as INXN-4001 is the first investigational new drug (IND) application filed and the first patient dosed for Precigen as a newly formed wholly-owned subsidiary of Intrexon," said Helen Sabzevari, PhD, president of Precigen.